Refine
Year of publication
Document Type
- Article (203)
- Preprint (38)
- Contribution to a Periodical (4)
Has Fulltext
- yes (245)
Is part of the Bibliography
- no (245)
Keywords
- SARS-CoV-2 (10)
- COVID-19 (5)
- Solution NMR-spectroscopy (4)
- COVID19-NMR (3)
- Covid19-NMR (3)
- Non-structural protein (3)
- risk factors (3)
- ACLF (2)
- Biomarkers (2)
- Collectivity (2)
- Correlation (2)
- Diffraction (2)
- Elastic scattering (2)
- Immunology (2)
- Mitochondria (2)
- Non-small cell lung cancer (2)
- Portal hypertension (2)
- Protein drugability (2)
- Shear viscosity (2)
- Solution NMR spectroscopy (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- aging (2)
- cirrhosis (2)
- inflammation (2)
- portal hypertension (2)
- (Hydroxymethyl)diphenyl(piperidinoalkyl)silanes (1)
- 32D progenitor cells (1)
- 3years (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 5′-UTR (1)
- ABCB1 (1)
- ABCC1 (1)
- ADGRE1 (1)
- ALK-rearranged NSCLC (1)
- AML (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute kidney injury (1)
- Advanced stage (1)
- Alpha-synuclein (1)
- Alternative oxidase (1)
- American crocodile (1)
- Angiogenesis (1)
- Angiography (1)
- Ankylosierende Spondylitis (1)
- Ankylosing spondylitis (1)
- Artificial Intelligence (1)
- Atmospheric chemistry (1)
- Axial spondyloarthritis (1)
- Axiale Spondyloarthritis (1)
- B-slope (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- BRVO (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Blood (1)
- Blood loss (1)
- Blood plasma (1)
- Botanical Collections (1)
- Brain tumor (1)
- CAKUT (1)
- CBA (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COPD (1)
- COVID (1)
- CV9202 (1)
- CVD biomarker (1)
- Cancer (1)
- Cardiology (1)
- Care gaps (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Cirrhosis (1)
- Climate sciences (1)
- Climate-change impacts (1)
- Clinical trial (1)
- Coalescence (1)
- Cohort studies (1)
- Cold nuclear matter effects (1)
- Colloids (1)
- Complex II (1)
- Complicated stage (1)
- Conservation (1)
- Critical point (1)
- Crocodylus acutus (1)
- Cryptic species (1)
- DME (1)
- Data sharing (1)
- Deuteron production (1)
- Devic disease (1)
- Devic syndrome (1)
- Di-hadron correlations (1)
- Diabetes (1)
- Digitization (1)
- Dimerization domain (1)
- Drug resistance (1)
- Drug targets (1)
- EMR1 (1)
- EWSR1 (1)
- Elliptic flow (1)
- Emphysema (1)
- Everolimus (1)
- Extended donor criteria (1)
- F4/80 (1)
- FOXO3a (1)
- G3BP (1)
- Gene fusion (1)
- Genetic testing (1)
- Genetics (1)
- Germany (1)
- Graft function (1)
- Graft survival (1)
- Groomed jet radius (1)
- HES (1)
- Hadronization (1)
- Haematocrit (1)
- Hashimoto’s thyroiditis (1)
- Health care (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heat shock protein 27 (1)
- Heavy Ion Experiments (1)
- Heavy Quark Production (1)
- Heavy ion collisions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-ion collisions (1)
- Helpline (1)
- Herbaria (1)
- Higher moments (1)
- Hydroxyethyl starch (1)
- Hypofractionated radiotherapy (1)
- IL-6 (1)
- ILUVIEN (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- Interference fragmentation function (1)
- J/ψ suppression (1)
- JAK2V617F (1)
- Jet substructure (1)
- K3EDTA plasma sampling (1)
- Kidney transplantation (1)
- LEOSS (1)
- Lipidomics (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Ltbp4 (1)
- MCP (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Macrodomain (1)
- Marginal grafts (1)
- Mean erythrocyte volume (1)
- Medication Appropriateness Index (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metabolomics (1)
- Mitochondrial disease (1)
- Molecular diagnostic testing (1)
- Molecular medicine (1)
- Mortality (1)
- Multiple parton interactions (1)
- Muscarinic Antagonists (1)
- Muscarinic Receptors (1)
- NAFL (1)
- NAFLD (1)
- NASH (1)
- NMO-IgG (1)
- NMR spectroscopy (1)
- Nephrons (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Nrf2 (1)
- Nucleic acid-binding domain (1)
- Nucleocapsid (1)
- Number of platelets (1)
- Ocean sciences (1)
- Oncology (1)
- Organ rinse (1)
- Organ shortage (1)
- Oxidative phosphorylation (1)
- PATZ1 (1)
- PTDM (1)
- Palaeoceanography (1)
- Palaeoclimate (1)
- Parkinson’s disease (1)
- Pdgfrβ (1)
- Pediatric (1)
- Periodontitis grades B and C (1)
- Phylogeny (1)
- Polo-like kinase 3 (1)
- Portal veins (1)
- Post-transplant (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary prophylaxis (1)
- Protein druggability (1)
- Proteins (1)
- Proton-proton collisions (1)
- Proton–proton collisions (1)
- Psychiatric disorders (1)
- Quality of care (1)
- Quality standards (1)
- Qualitätsstandards (1)
- Quarkonium (1)
- RHIC (1)
- RNA genome (1)
- ROS (1)
- Radical nephrectomy (1)
- Rare diseases (1)
- Registries (1)
- Renal cancer (1)
- Renal system (1)
- Research Infrastructure (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Rho GTPases (1)
- SD-OCT (1)
- SL1 (1)
- SLC20A1 (1)
- SOFA (1)
- SPSS (1)
- STK3 (1)
- Sampling protocol (1)
- Semantics (1)
- Sepsis (1)
- Septic shock (1)
- Sila-difenidol (1)
- Sila-pridinol (1)
- SoftDrop (1)
- Splitting function (1)
- Spontaneous bacterial peritonitis (1)
- Steroid (1)
- Structural protein (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- TGR(mREN2)27 (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Tacrolimus (1)
- Taxonomy (1)
- Telemedicine (1)
- Tgfβ (1)
- Thermal model (1)
- Transversity (1)
- Trauma (1)
- UCN-01 (1)
- VEGF (1)
- Versorgungslücken (1)
- Versorgungsqualität (1)
- Volume therapy (1)
- Western diet (1)
- White blood cells (1)
- YM155 (1)
- accessory proteins (1)
- accident (1)
- acute decompensation (1)
- acute-on-chronic liver failure (ACLF) (1)
- adhesion (1)
- advanced care planning (1)
- aftercare structures (1)
- ambulatory assessment (1)
- anal carcinoma (1)
- anticonvulsants (1)
- aquaporin-4 (AQP4) antibody (1)
- bioactivity testing (1)
- bladder exstrophy-epispadias complex (1)
- bleeding (1)
- cancer (1)
- caspase-8 (1)
- cell-free expression (1)
- cell-free protein synthesis (1)
- cerebrospinal fluid (1)
- chemoradiotherapy (1)
- chronic kidney disease (1)
- chronic myeloid leukemia (1)
- clinical features (1)
- cloacal malformation (1)
- comorbidities (1)
- computed tomography (1)
- computer-assisted drug therapy (1)
- consensus (1)
- context (1)
- critically ill patients (1)
- cytarabine dose (1)
- day clinic (1)
- decompensated liver cirrhosis (1)
- differentiated thyroid carcinoma (1)
- drug resistance (1)
- dysbiosis (1)
- easyPACId (1)
- ectosomes (1)
- elderly (1)
- epidemiology (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- essential thrombocythemia (ET) (1)
- exosomes (1)
- experience sampling (1)
- extracellular vesicles (1)
- functional genetics (1)
- global change (1)
- glycobiology (1)
- glycoconjugate (1)
- guidelines (1)
- habitat destruction (1)
- health information exchange (1)
- hepatic encephalopathy (1)
- homing (1)
- hospital admission (1)
- immunity (1)
- infectious disease (1)
- injury (1)
- intrinsically disordered region (1)
- kidney formation (1)
- land use (1)
- lasso regression (1)
- lethal toxin (1)
- levetiracetam (1)
- liver (1)
- liver fibrosis (1)
- liver transplantation (1)
- liver transplantation center (1)
- local control (1)
- lockdown (1)
- long-term outcome (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magnetic resonance imaging (1)
- male (1)
- mechanical ventilation (1)
- medication reconciliation (1)
- metabolic reprogramming (1)
- metabolic syndromes (1)
- microbiome (1)
- microdosing (1)
- microparticles (1)
- microvesicles (1)
- migration (1)
- minimal information requirements (1)
- mitosis (1)
- molecular modeling (1)
- molecular switch (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mortality (1)
- mtDNA (1)
- multimodal complex treatment (1)
- multimorbidity (1)
- multiple chronic conditions (1)
- myeloproliferative neoplasms (MPN) (1)
- nanodiscs (1)
- natural products (1)
- networks (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological manifestations (1)
- neutralizing antibodies (1)
- nomogram (1)
- nonstructural proteins (1)
- p+p collisions (1)
- pediatric intensive care (1)
- peptide antibiotics (1)
- peri-implantitis (1)
- personalized medicine (1)
- phage lysis proteins (1)
- polycythemia vera (PV) (1)
- polypharmacy (1)
- portosystemic shunt (1)
- post-liver transplantation management (1)
- primary myelofibrosis (PMF) (1)
- proteobacteria (1)
- proteomics (1)
- pulmonary failure (1)
- qualitative research (1)
- quality control (1)
- rare diseases (1)
- real-life study (1)
- recurrent optic neuritis (1)
- renal dysfunction (1)
- reproducibility (1)
- respiratory failure (1)
- retrovirus (1)
- rigor (1)
- risk factor progression (1)
- risk stratification (1)
- seizure (1)
- sequential ALK-inhibitor therapy (1)
- sialic acid (1)
- simplified production (1)
- sirtuin1 (1)
- situation (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- standardization (1)
- structural proteins (1)
- survival (1)
- survivin (1)
- thromboembolism (1)
- thrombosis (1)
- toxin B (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- trauma (1)
- tyrosine kinase inhibitors. (1)
- urinary tract development (1)
- variants of concern (1)
- vitamin D (1)
- vitamin D receptor (1)
- vitreous samples (1)
- zebrafish development (1)
Institute
The emerging disciplines of lipidomics and metabolomics show great potential for the discovery of diagnostic biomarkers, but appropriate pre-analytical sample-handling procedures are critical because several analytes are prone to ex vivo distortions during sample collection. To test how the intermediate storage temperature and storage period of plasma samples from K3EDTA whole-blood collection tubes affect analyte concentrations, we assessed samples from non-fasting healthy volunteers (n = 9) for a broad spectrum of metabolites, including lipids and lipid mediators, using a well-established LC-MS-based platform. We used a fold change-based approach as a relative measure of analyte stability to evaluate 489 analytes, employing a combination of targeted LC-MS/MS and LC-HRMS screening. The concentrations of many analytes were found to be reliable, often justifying less strict sample handling; however, certain analytes were unstable, supporting the need for meticulous processing. We make four data-driven recommendations for sample-handling protocols with varying degrees of stringency, based on the maximum number of analytes and the feasibility of routine clinical implementation. These protocols also enable the simple evaluation of biomarker candidates based on their analyte-specific vulnerability to ex vivo distortions. In summary, pre-analytical sample handling has a major effect on the suitability of certain metabolites as biomarkers, including several lipids and lipid mediators. Our sample-handling recommendations will increase the reliability and quality of samples when such metabolites are necessary for routine clinical diagnosis.
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection
(2008)
Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrhosis, often have severe consequences for the patient. Because of a lack of appropriate animal models, not much is known about their potential viral etiology. Infection by liver-tropic viruses is one possibility for the breakdown of self-tolerance. Therefore, we infected mice with adenovirus Ad5 expressing human cytochrome P450 2D6 (Ad-2D6). Ad-2D6–infected mice developed persistent autoimmune liver disease, apparent by cellular infiltration, hepatic fibrosis, “fused” liver lobules, and necrosis. Similar to type 2 AIH patients, Ad-2D6–infected mice generated type 1 liver kidney microsomal–like antibodies recognizing the immunodominant epitope WDPAQPPRD of cytochrome P450 2D6 (CYP2D6). Interestingly, Ad-2D6–infected wild-type FVB/N mice displayed exacerbated liver damage when compared with transgenic mice expressing the identical human CYP2D6 protein in the liver, indicating the presence of a stronger immunological tolerance in CYP2D6 mice. We demonstrate for the first time that infection with a virus expressing a natural human autoantigen breaks tolerance, resulting in a chronic form of severe, autoimmune liver damage. Our novel model system should be instrumental for studying mechanisms involved in the initiation, propagation, and precipitation of virus-induced autoimmune liver diseases.
Background: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort. Methods: A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls. Results: The median observation time was 11.11 years. The nine-year event-free survival rates were 41 ± 4%, 31 ± 5%, and 32 ± 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ± 5%, p = 0.026) and to no consolidation (35 ± 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found. Conclusions: Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
Qualitätsstandards (QS) sind messbare Konstrukte, die helfen sollen, Versorgungslücken quantitativ zu erfassen, um langfristig die Versorgungsqualität zu verbessern. Die Assessment of SpondyloArthritis International Society (ASAS) hat kürzlich erstmals internationale QS für das Management von Patient*innen mit axialer Spondyloarthritis (axSpA) konsentiert und veröffentlicht. Die Deutsche Gesellschaft für Rheumatologie (DGRh) hat daraufhin beschlossen, diese Standards durch eine Gruppe von Expert*innen aus unterschiedlichen Versorgungsbereichen zu übersetzen, zu prüfen und ggf. zu übernehmen. Vor diesem Hintergrund wurden erstmals nationale QS für das Management von Patient*innen mit axSpA für Deutschland entwickelt. Hierbei wurde v. a. auf Machbarkeit und Praxisrelevanz geachtet. Letztlich wurden 9 QS definiert, mit denen die Qualität der Versorgung in Deutschland gemessen und verbessert werden kann bzw. soll.
Tyrosine kinase inhibitors (TKIs) are currently the standard chemotherapeutic agents for the treatment of chronic myeloid leukemia (CML). However, due to TKI resistance acquisition in CML patients, identification of new vulnerabilities is urgently required for a sustained response to therapy. In this study, we have investigated metabolic reprogramming induced by TKIs independent of BCR-ABL1 alterations. Proteomics and metabolomics profiling of imatinib-resistant CML cells (ImaR) was performed. KU812 ImaR cells enhanced pentose phosphate pathway, glycogen synthesis, serine-glycine-one-carbon metabolism, proline synthesis and mitochondrial respiration compared with their respective syngeneic parental counterparts. Moreover, the fact that only 36% of the main carbon sources were utilized for mitochondrial respiration pointed to glycerol-phosphate shuttle as mainly contributors to mitochondrial respiration. In conclusion, CML cells that acquire TKIs resistance present a severe metabolic reprogramming associated with an increase in metabolic plasticity needed to overcome TKI-induced cell death. Moreover, this study unveils that KU812 Parental and ImaR cells viability can be targeted with metabolic inhibitors paving the way to propose novel and promising therapeutic opportunities to overcome TKI resistance in CML.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
Background: Rare diseases are, by definition, very serious and chronic diseases with a high negative impact on quality of life. Approximately 350 million people worldwide live with rare diseases. The resulting high disease burden triggers health information search, but helpful, high-quality, and up-to-date information is often hard to find. Therefore, the improvement of health information provision has been integrated in many national plans for rare diseases, discussing the telephone as one access option. In this context, this study examines the need for a telephone service offering information for people affected by rare diseases, their relatives, and physicians.
Methods: In total, 107 individuals participated in a qualitative interview study conducted in Germany. Sixty-eight individuals suffering from a rare disease or related to somebody with rare diseases and 39 health care professionals took part. Individual interviews were conducted using a standardized semi-structured questionnaire. Interviews were analysed using the qualitative content analysis, triangulating patients, relatives, and health care professionals. The fulfilment of qualitative data processing standards has been controlled for.
Results: Out of 68 patients and relatives and 39 physicians, 52 and 18, respectively, advocated for the establishment of a rare diseases telephone service. Interviewees expected a helpline to include expert staffing, personal contact, good availability, low technical barriers, medical and psychosocial topics of counselling, guidance in reducing information chaos, and referrals. Health care professionals highlighted the importance of medical topics of counselling—in particular, differential diagnostics—and referrals.
Conclusions: Therefore, the need for a national rare diseases helpline was confirmed in this study. Due to limited financial resources, existing offers should be adapted in a stepwise procedure in accordance with the identified attributes.
Background: Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal über seltene Erkrankungen, ZIPSE).
Objective: The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers.
Methods: We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal.
Results: A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions.
Conclusions: The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases.
Registered Report Identifier: RR1-10.2196/7425.
An important question concerning inter-areal communication in the cortex, is whether these interactions are synergistic, i.e. convey information beyond what can be performed by isolated signals. Here, we dissociated cortical interactions sharing common information from those encoding complementary information during prediction error processing. To this end, we computed co-information, an information-theoretical measure that distinguishes redundant from synergistic information among brain signals. We analyzed auditory and frontal electrocorticography (ECoG) signals in three common awake marmosets and investigated to what extent event-related-potentials (ERP) and broadband (BB) dynamics exhibit redundancy and synergy in auditory prediction error signals. We observed multiple patterns of redundancy and synergy across the entire cortical hierarchy with distinct dynamics. The information conveyed by ERPs and BB signals was highly synergistic even at lower stages of the hierarchy in the auditory cortex, as well as between lower and higher areas in the frontal cortex. These results indicate that the distributed representations of prediction error signals across the cortical hierarchy can be highly synergistic.
The ability of hematopoietic stem cells (HSCs) to self-renew is a prerequisite for the establishment of definitive hematopoiesis and life-long blood regeneration. Here, we report the single-stranded DNA-binding transcriptional regulator far upstream element (FUSE)-binding protein 1 (FUBP1) as an essential factor of HSC self-renewal. Functional inactivation of FUBP1 in two different mouse models resulted in embryonic lethal anemia at around E15.5 caused by severely diminished HSCs. Fetal and adult HSCs lacking FUBP1 revealed an HSC-intrinsic defect in their maintenance, expansion, and long-term blood reconstitution, but could differentiate into all hematopoietic lineages. FUBP1-deficient adult HSCs exhibit significant transcriptional changes, including upregulation of the cell-cycle inhibitor p21 and the pro-apoptotic Noxa molecule. These changes caused an increase in generation time and death of HSCs as determined by video-microscopy-based tracking. Our data establish FUBP1 and its recognition of single-stranded genomic DNA as an important element in the transcriptional regulation of HSC self-renewal.
Novel treatment options are needed for the successful therapy of patients with high-risk neuroblastoma. Here, we investigated the cyclin-dependent kinase (CDK) inhibitor SNS-032 in a panel of 109 neuroblastoma cell lines consisting of 19 parental cell lines and 90 sublines with acquired resistance to 14 different anticancer drugs. Seventy-three percent of the investigated neuroblastoma cell lines and all four investigated primary tumor samples displayed concentrations that reduce cell viability by 50% in the range of the therapeutic plasma levels reported for SNS-032 (<754 nM). Sixty-two percent of the cell lines and two of the primary samples displayed concentrations that reduce cell viability by 90% in this concentration range. SNS-032 also impaired the growth of the multidrug-resistant cisplatin-adapted UKF-NB-3 subline UKF-NB-3rCDDP1000 in mice. ABCB1 expression (but not ABCG2 expression) conferred resistance to SNS-032. The antineuroblastoma effects of SNS-032 did not depend on functional p53. The antineuroblastoma mechanism of SNS-032 included CDK7 and CDK9 inhibition-mediated suppression of RNA synthesis and subsequent depletion of antiapoptotic proteins with a fast turnover rate including X-linked inhibitor of apoptosis (XIAP), myeloid cell leukemia sequence 1 (Mcl-1), baculoviral IAP repeat containing 2 (BIRC2; cIAP-1), and survivin. In conclusion, CDK7 and CDK9 represent promising drug targets and SNS-032 represents a potential treatment option for neuroblastoma including therapy-refractory cases.
Species distributed across vast continental areas and across major biomes provide unique model systems for studies of biotic diversification, yet also constitute daunting financial, logistic and political challenges for data collection across such regions. The tree frog Dendropsophus minutus (Anura: Hylidae) is a nominal species, continentally distributed in South America, that may represent a complex of multiple species, each with a more limited distribution. To understand the spatial pattern of molecular diversity throughout the range of this species complex, we obtained DNA sequence data from two mitochondrial genes, cytochrome oxidase I (COI) and the 16S rhibosomal gene (16S) for 407 samples of D. minutus and closely related species distributed across eleven countries, effectively comprising the entire range of the group. We performed phylogenetic and spatially explicit phylogeographic analyses to assess the genetic structure of lineages and infer ancestral areas. We found 43 statistically supported, deep mitochondrial lineages, several of which may represent currently unrecognized distinct species. One major clade, containing 25 divergent lineages, includes samples from the type locality of D. minutus. We defined that clade as the D. minutus complex. The remaining lineages together with the D. minutus complex constitute the D. minutus species group. Historical analyses support an Amazonian origin for the D. minutus species group with a subsequent dispersal to eastern Brazil where the D. minutus complex originated. According to our dataset, a total of eight mtDNA lineages have ranges >100,000 km2. One of them occupies an area of almost one million km2 encompassing multiple biomes. Our results, at a spatial scale and resolution unprecedented for a Neotropical vertebrate, confirm that widespread amphibian species occur in lowland South America, yet at the same time a large proportion of cryptic diversity still remains to be discovered.
Background The arterial in line application of the leukocyte inhibition module (LIM) in the cardiopulmonary bypass (CPB) limits overshooting leukocyte activity during cardiac surgery. We now studied in a porcine model whether LIM may have beneficial effects on cardiac function after CPB. Methods German landrace pigs underwent CPB (60 min myocardial ischemia; 30 min reperfusion)without (group I; n=6) or with LIM (group II; n=6). The cardiac indices (CI) and cardiac function were analyzed pre and post CPB with a Swan-Ganz catheter and the cardiac function analyzer. Neutrophil labeling with technetium, scintigraphy, and histological analyses were done to track activated neutrophils within the organs. Results LIM prevented CPB-associated increase of neutrophil counts in peripheral blood. In group I, the CI significantly declined post CPB (post: 3.26 +/- 0.31; pre: 4.05 +/- 0.45 l/min/m2; p<0.01). In group II, the CI was only slightly reduced (post: 3.86 +/- 0.49; pre 4.21 +/- 1.32 l/min/m2; p=0.23). Post CPB, the intergroup difference showed significantly higher CI values in the LIM group (p<0.05) which was in conjunction with higher pre-load independent endsystolic pressure volume relationship (ESPVR) values (group I: 1.57 +/- 0.18; group II: 1.93 +/- 0.16; p<0.001). Moreover, the systemic vascular resistance and pulmonary vascular resistance were lower in the LIM group. LIM appeared to accelerate the sequestration of hyperactivated neutrophils in the spleen and to reduce neutrophil infiltration of heart and lung. Conclusions Our data provide strong evidence that LIM improves perioperative hemodynamics and cardiac function after CPB by limiting neutrophil activity and inducing accelerated sequestration of neutrophils in the spleen.
We have isolated the human protein SNEV as downregulated in replicatively senescent cells. Sequence homology to the yeast splicing factor Prp19 suggested that SNEV might be the orthologue of Prp19 and therefore might also be involved in pre-mRNA splicing. We have used various approaches including gene complementation studies in yeast using a temperature sensitive mutant with a pleiotropic phenotype and SNEV immunodepletion from human HeLa nuclear extracts to determine its function. A human–yeast chimera was indeed capable of restoring the wild-type phenotype of the yeast mutant strain. In addition, immunodepletion of SNEV from human nuclear extracts resulted in a decrease of in vitro pre-mRNA splicing efficiency. Furthermore, as part of our analysis of protein–protein interactions within the CDC5L complex, we found that SNEV interacts with itself. The self-interaction domain was mapped to amino acids 56–74 in the protein's sequence and synthetic peptides derived from this region inhibit in vitro splicing by surprisingly interfering with spliceosome formation and stability. These results indicate that SNEV is the human orthologue of yeast PRP19, functions in splicing and that homo-oligomerization of SNEV in HeLa nuclear extract is essential for spliceosome assembly and that it might also be important for spliceosome stability.
Siglec-1 (sialoadhesin, CD169) is a surface receptor on human cells that mediates trans-enhancement of HIV-1 infection through recognition of sialic acid moieties in virus membrane gangliosides. Here, we demonstrate that mouse Siglec-1, expressed on the surface of primary macrophages in an interferon-α-responsive manner, captures murine leukemia virus (MLV) particles and mediates their transfer to proliferating lymphocytes. The MLV infection of primary B-cells was markedly more efficient than that of primary T-cells. The major structural protein of MLV particles, Gag, frequently co-localized with Siglec-1, and trans-infection, primarily of surface-bound MLV particles, efficiently occurred. To explore the role of sialic acid for MLV trans-infection at a submolecular level, we analyzed the potential of six sialic acid precursor analogs to modulate the sialylated ganglioside-dependent interaction of MLV particles with Siglec-1. Biosynthetically engineered sialic acids were detected in both the glycolipid and glycoprotein fractions of MLV producer cells. MLV released from cells carrying N-acyl-modified sialic acids displayed strikingly different capacities for Siglec-1-mediated capture and trans-infection; N-butanoyl, N-isobutanoyl, N-glycolyl, or N-pentanoyl side chain modifications resulted in up to 92 and 80% reduction of virus particle capture and trans-infection, respectively, whereas N-propanoyl or N-cyclopropylcarbamyl side chains had no effect. In agreement with these functional analyses, molecular modeling indicated reduced binding affinities for non-functional N-acyl modifications. Thus, Siglec-1 is a key receptor for macrophage/lymphocyte trans-infection of surface-bound virions, and the N-acyl side chain of sialic acid is a critical determinant for the Siglec-1/MLV interaction.
Starting from (MeO)3SiCH2Cl (10) and Ph2(H)SiCH2OH (16), respectively, the (hydroxymethyl)diphenyl(piperidinoalkyl)silanes (HOCH2)Ph2Si(CH2)2NC5H10 (6) and (HOCH2)Ph2Si(CH2)3NC5H10 (8) have been synthesized [10→Ph2(MeO)SiCH2Cl (11)→Ph2(CH2=CH)SiCH2Cl (12)→Ph2(CH2=CH)SiCH2OAc (13)→Ph2(CH2=CH)SiCH2OH (14)→Ph2(CH2=CH)SiCH2OSiMe3 (15)→6; 16→Ph2(H)SiCH2OSiMe3 (17)→8; NC5H10 = piperidino]. N-Quaternization of 6 and 8 with MeI gave the corresponding methiodides 7 and 9, respectively. As shown by IR-spectroscopic studies, compounds 6 and 8 form intramolecular O-H···N hydrogen bonds in solution (CCl4). In the crystal, 6 (space group Pna21; two crystallographically independent molecules) also forms intramolecular O-H···N hydrogen bonds whereas 8 (space group P1̅) forms intermolecular O-H···N hydrogen bonds leading to the formation of centrosymmetric dimers (single-crystal X-ray diffraction studies). The (hydroxymethyl) silanes 6-9 and the related silanols (HO)Ph2Si(CH2)2NC5H 10 (sila-pridinol; 1), sila-pridinol methiodide (2), (HO)Ph2Si(CH2)3NC5H10 (sila-difenidol; 3) and sila-difenidol methiodide (4) were investigated for their antimuscarinic properties. In functional pharmacological experiments as well as in radioligand competition studies, all compounds behaved as simple competitive antagonists at muscarinic M1-, M2-, M3- and M4-receptors. In general, the silanols 1-4 displayed higher receptor affinities (up to 100-fold) than the corresponding (hydroxymethyl) silanes 6-9 . In the (hydroxymethyl)silane series, compound 7 was found to be the most potent muscarinic antagonist [pA2/pKi= 8,71/8,6 (M1), 8,23/7,8 (M2), 8,19/7,8 (M3); pKi = 8,2 (M4)]. In the silanol series, the related compound 2 showed the most interesting antimuscarinic properties [pA2/pKi = 10,37/9,6 (M1), 8,97/8,8 (M2), 9,08/8,8 (M3); pKi = 9,4 (M4)].
The development of resistance to chemotherapeutic agents, such as Doxorubicin (DOX) and cytarabine (AraC), is one of the greatest challenges to the successful treatment of Acute Myeloid Leukemia (AML). Such acquisition is often underlined by a metabolic reprogramming that can provide a therapeutic opportunity, as it can lead to the emergence of vulnerabilities and dependencies to be exploited as targets against the resistant cells. In this regard, genome-scale metabolic models (GSMMs) have emerged as powerful tools to integrate multiple layers of data to build cancer-specific models and identify putative metabolic vulnerabilities. Here, we use genome-scale metabolic modelling to reconstruct a GSMM of the THP1 AML cell line and two derivative cell lines, one with acquired resistance to AraC and the second with acquired resistance to DOX. We also explore how, adding to the transcriptomic layer, the metabolomic layer enhances the selectivity of the resulting condition specific reconstructions. The resulting models enabled us to identify and experimentally validate that drug-resistant THP1 cells are sensitive to the FDA-approved antifolate methotrexate. Moreover, we discovered and validated that the resistant cell lines could be selectively targeted by inhibiting squalene synthase, providing a new and promising strategy to directly inhibit cholesterol synthesis in AML drug resistant cells.
Measurement of groomed jet substructure observables in p+p collisions at √s = 200 GeV with STAR
(2020)
In this letter, measurements of the shared momentum fraction (zg) and the groomed jet radius (Rg), as defined in the SoftDrop algorithm, are reported in p+p collisions at √s = 200 GeV collected by the STAR experiment. These substructure observables are differentially measured for jets of varying resolution parameters from R = 0.2 − 0.6 in the transverse momentum range 15 < pT,jet < 60 GeV/c. These studies show that, in the pT,jet range accessible at √s = 200 GeV and with increasing jet resolution parameter and jet transverse momentum, the zg distribution asymptotically converges to the DGLAP splitting kernel for a quark radiating a gluon. The groomed jet radius measurements reflect a momentum-dependent narrowing of the jet structure for jets of a given resolution parameter, i.e., the larger the pT,jet, the narrower the first splitting. For the first time, these fully corrected measurements are compared to Monte Carlo generators with leading order QCD matrix elements and leading log in the parton shower, and to state-of-the-art theoretical calculations at next-to-leading-log accuracy. We observe that PYTHIA 6 with parameters tuned to reproduce RHIC measurements is able to quantitatively describe data, whereas PYTHIA 8 and HERWIG 7, tuned to reproduce LHC data, are unable to provide a simultaneous description of both zg and Rg, resulting in opportunities for fine parameter tuning of these models for p+p collisions at RHIC energies. We also find that the theoretical calculations without non-perturbative corrections are able to qualitatively describe the trend in data for jets of large resolution parameters at high pT,jet, but fail at small jet resolution parameters and low jet transverse momenta.
Investigation of the linear and mode-coupled flow harmonics in Au+Au collisions at √sNN = 200 GeV
(2020)
Flow harmonics (vn) of the Fourier expansion for the azimuthal distributions of hadrons are commonly employed to quantify the azimuthal anisotropy of particle production relative to the collision symmetry planes. While lower order Fourier coefficients (v2 and v3) are more directly related to the corresponding eccentricities of the initial state, the higher-order flow harmonics (vn>3) can be induced by a modecoupled response to the lower-order anisotropies, in addition to a linear response to the same-order anisotropies. These higher-order flow harmonics and their linear and mode-coupled contributions can be used to more precisely constrain the initial conditions and the transport properties of the medium in theoretical models. The multiparticle azimuthal cumulant method is used to measure the linear and mode-coupled contributions in the higher-order anisotropic flow, the mode-coupled response coefficients, and the correlations of the event plane angles for charged particles as functions of centrality and transverse momentum in Au+Au collisions at nucleon-nucleon center-of-mass energy √sN N= 200 GeV. The results are compared to similar LHC measurements as well as to several viscous hydrodynamic calculations with varying initial conditions.